{"id":15471,"date":"2026-06-03T18:00:00","date_gmt":"2026-06-03T16:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=0e61e73e08126f4c8495c3886cf97adb"},"modified":"2026-06-03T18:00:00","modified_gmt":"2026-06-03T16:00:00","slug":"ocs-investor-alert-levi-korsinsky-investigates-oculis-holding-ag-ocs-for-potential-securities-fraud","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=15471","title":{"rendered":"OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud"},"content":{"rendered":"

\nOculis Holding AG shares lost over 23% of their value in a single session after Phase 3 DIAMOND trial results revealed OCS-01 failed to meet its primary endpoint in diabetic macular edema.<\/i><\/p><\/a><\/a>

NEW YORK--(BUSINESS WIRE)--Shareholders of Oculis Holding AG (NASDAQ: OCS) lost nearly $7 per share, more than 23%, in a single trading session when the company disclosed that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet the primary endpoint -- mean change in best-corrected visual acuity at week 52 -- in diabetic macular edema. Oculis simultaneously announced it would not pursue an FDA filing for the DME indication. Investors who lost money on OCS are encouraged to submit their information now<\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>

\nThe approximately 23.4% single-day decline followed disclosure that OCS-01 eye drops -- the company's lead pipeline candidate targeting what Oculis had described as a multi-billion-dollar market -- did not achieve statistical significance on the primary efficacy measure across both pivotal trials. The company stated it would redirect resources to other pipeline candidates and would not file a New Drug Application for the DME indication.<\/p>

\nPrior to the disclosure, Oculis had described the DIAMOND program as positioned for topline results in 2026 with a subsequent NDA submission planned for Q4 2026. CEO Sherif had previously claimed it was a product they \u201cknow that it works \u2026 really the only risk \u2026 is execution.\u201d Despite their claimed \u201cobsessive execution,\u201d the studies ultimately failed and the stock's 23% decline erased hundreds of millions of dollars in market capitalization in a single session.<\/p>

\nShareholders who purchased OCS and suffered a loss are encouraged to click here to discuss their legal rights<\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>

\nABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities investigations and recoveries. Ranked in ISS Top 50 for seven consecutive years.<\/p>

\nFrequently Asked Questions About the OCS Investigation<\/p>

\nQ: Who is eligible to participate in the OCS investigation?<\/b> A: Investors who purchased OCS stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.<\/p>

\nQ: How much did OCS stock drop?<\/b> A: Shares fell approximately 23% in a single trading session after the company disclosed that Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet the primary endpoint in diabetic macular edema and announced it would not pursue an FDA filing for that indication.<\/p>

\nQ: What do OCS investors need to do right now?<\/b> A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com<\/a> or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.<\/p>

\nQ: What if I already sold my OCS shares -- can I still recover losses?<\/b> A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought OCS and sold at a loss may still participate in the investigation.<\/p>

\nQ: What does it cost me to participate?<\/b> A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.<\/p>

\nQ: Do I need to go to court or give testimony?<\/b> A: No. Participating in the investigation does not require court appearances or depositions. The overwhelming majority of affected investors never appear in court.<\/p> Contacts<\/b>

\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com<\/a>Tel: (212) 363-7500\nFax: (212) 363-7171<\/p>","protected":false},"excerpt":{"rendered":"

Oculis Holding AG shares lost over 23% of their value in a single session after Phase 3 DIAMOND trial results revealed OCS-01 failed to meet its primary endpoint in diabetic macular edema.NEW YORK–(BUSINESS WIRE)–Shareholders of Oculis Holding AG (N…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-15471","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15471"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15471\/revisions"}],"predecessor-version":[{"id":15472,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15471\/revisions\/15472"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}